Simple Stochastic Fingerprints Towards Mathematical Modeling in Biology and Medicine 2. Unifying Markov Model for Drugs Side Effects

Drug Side-Effect Profiles Prediction: From Empirical to Structural Risk Minimization

The identification of drug side-effects is considered to be an important step in drug design, which could not only shorten the time but also reduce the cost of drug development. In this paper, we investigate the relationship between the potential side-effects of drug candidates and their chemical structures. The preliminary Regularized Regression (RR) model for drug side-effects prediction has promising features in the efficiency of model training and the existence of a closed form solution. It performs better than other state-of-the-art methods, in terms of minimum accuracy and average accuracy. In order to dig inside how drug structure will associate with side effect, we further propose weighted GTS (Generalized T-Student Kernel: WGTS) SVM model from a structural risk minimization perspective. The SVM model proposed in this paper provides a better understanding of drug side-effects in the process of drug development. The usefulness of the WGTS model lies in the superior performance in a cross validation setting on 888 approved drugs with 1385 side-effects profiling from SIDER database. This work is expected to shed light on intriguing studies that predict potential un-identifying side-effects and suggest how we can avoid drug side-effects by the removal of some distinguished chemical structures.

In silico assessment of adverse drug reactions and associated mechanisms

During recent years, various in silico approaches have been developed to estimate chemical and biological drug features, for example chemical fragments, protein targets, pathways, among others, that correlate with adverse drug reactions (ADRs) and explain the associated mechanisms. These features have also been used for the creation of predictive models that enable estimation of ADRs during the early stages of drug development. In this review, we discuss various in silico approaches to predict these features for a certain drug, estimate correlations with ADRs, establish causal relationships between selected features and ADR mechanisms and create corresponding predictive models.

A new approach to identify, classify and count drug-related events

AIMS

The incidence of clinical events related to medication errors and/or adverse drug reactions reported in the literature varies by a degree that cannot solely be explained by the clinical setting, the varying scrutiny of investigators or varying definitions of drug-related events. Our hypothesis was that the individual complexity of many clinical cases may pose relevant limitations for current definitions and algorithms used to identify, classify and count adverse drug-related events.

METHODS

Based on clinical cases derived from an observational study we identified and classified common clinical problems that cannot be adequately characterized by the currently used definitions and algorithms.

RESULTS

It appears that some key models currently used to describe the relation of medication errors (MEs), adverse drug reactions (ADRs) and adverse drug events (ADEs) can easily be misinterpreted or contain logical inconsistencies that limit their accurate use to all but the simplest clinical cases. A key limitation of current models is the inability to deal with complex interactions such as one drug causing two clinically distinct side effects or multiple drugs contributing to a single clinical event. Using a large set of clinical cases we developed a revised model of the interdependence between MEs, ADEs and ADRs and extended current event definitions when multiple medications cause multiple types of problems. We propose algorithms that may help to improve the identification, classification and counting of drug-related events.

CONCLUSIONS

The new model may help to overcome some of the limitations that complex clinical cases pose to current paper- or software-based drug therapy safety.

An algorithmic framework for predicting side effects of drugs

One of the critical stages in drug development is the identification of potential side effects for promising drug leads. Large-scale clinical experiments aimed at discovering such side effects are very costly and may miss subtle or rare side effects. Previous attempts to systematically predict side effects are sparse and consider each side effect independently. In this work, we report on a novel approach to predict the side effects of a given drug, taking into consideration information on other drugs and their side effects. Starting from a query drug, a combination of canonical correlation analysis and network-based diffusion is applied to predict its side effects. We evaluate our method by measuring its performance in a cross validation setting using a comprehensive data set of 692 drugs and their known side effects derived from package inserts. For 34% of the drugs, the top scoring side effect matches a known side effect of the drug. Remarkably, even on unseen data, our method is able to infer side effects that highly match existing knowledge. In addition, we show that our method outperforms a prediction scheme that considers each side effect separately. Our method thus represents a promising step toward shortcutting the process and reducing the cost of side effect elucidation.

Non-linear models based on simple topological indices to identify RNase III protein members

Alignment-free classifiers are especially useful in the functional classification of protein classes with variable homology and different domain structures. Thus, the Topological Indices to BioPolymers (TI2BioP) methodology (Agüero-Chapin et al., 2010) inspired in both the TOPS-MODE and the MARCH-INSIDE methodologies allows the calculation of simple topological indices (TIs) as alignment-free classifiers. These indices were derived from the clustering of the amino acids into four classes of hydrophobicity and polarity revealing higher sequence-order information beyond the amino acid composition level. The predictability power of such TIs was evaluated for the first time on the RNase III family, due to the high diversity of its members (primary sequence and domain organization). Three non-linear models were developed for RNase III class prediction: Decision Tree Model (DTM), Artificial Neural Networks (ANN)-model and Hidden Markov Model (HMM). The first two are alignment-free approaches, using TIs as input predictors. Their performances were compared with a non-classical HMM, modified according to our amino acid clustering strategy. The alignment-free models showed similar performances on the training and the test sets reaching values above 90% in the overall classification. The non-classical HMM showed the highest rate in the classification with values above 95% in training and 100% in test. Although the higher accuracy of the HMM, the DTM showed simplicity for the RNase III classification with low computational cost. Such simplicity was evaluated in respect to HMM and ANN models for the functional annotation of a new bacterial RNase III class member, isolated and annotated by our group.

Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds

Several pathogen parasite species show different susceptibilities to different antiparasite drugs. Unfortunately, almost all structure-based methods are one-task or one-target Quantitative Structure-Activity Relationships (ot-QSAR) that predict the biological activity of drugs against only one parasite species. Consequently, multi-tasking learning to predict drugs activity against different species by a single model (mt-QSAR) is vitally important. In the two previous works of the present series we reported two single mt-QSAR models in order to predict the antimicrobial activity against different fungal (Bioorg. Med. Chem.2006, 14, 5973-5980) or bacterial species (Bioorg. Med. Chem.2007, 15, 897-902). These mt-QSARs offer a good opportunity (unpractical with ot-QSAR) to construct drug-drug similarity Complex Networks and to map the contribution of sub-structures to function for multiple species. These possibilities were unattended in our previous works. In the present work, we continue this series toward other important direction of chemotherapy (antiparasite drugs) with the development of an mt-QSAR for more than 500 drugs tested in the literature against different parasites. The data were processed by Linear Discriminant Analysis (LDA) classifying drugs as active or non-active against the different tested parasite species. The model correctly classifies 212 out of 244 (87.0%) cases in training series and 207 out of 243 compounds (85.4%) in external validation series. In order to illustrate the performance of the QSAR for the selection of active drugs we carried out an additional virtual screening of antiparasite compounds not used in training or predicting series; the model recognized 97 out of 114 (85.1%) of them. We also give the procedures to construct back-projection maps and to calculate sub-structures contribution to the biological activity. Finally, we used the outputs of the QSAR to construct, by the first time, a multi-species Complex Networks of antiparasite drugs. The network predicted has 380 nodes (compounds), 634 edges (pairs of compounds with similar activity). This network allows us to cluster different compounds and identify on average three known compounds similar to a new query compound according to their profile of biological activity. This is the first attempt to calculate probabilities of antiparasitic action of drugs against different parasites.

3D-MEDNEs: an alternative "in silico" technique for chemical research in toxicology. 2. quantitative proteome-toxicity relationships (QPTR) based on mass spectrum spiral entropy

Low range mass spectra (MS) characterization of serum proteome offers the best chance of discovering proteome-(early drug-induced cardiac toxicity) relationships, called here Pro-EDICToRs. However, due to the thousands of proteins involved, finding the single disease-related protein could be a hard task. The search for a model based on general MS patterns becomes a more realistic choice. In our previous work ( González-Díaz, H. , et al. Chem. Res. Toxicol. 2003, 16, 1318- 1327 ), we introduced the molecular structure information indices called 3D-Markovian electronic delocalization entropies (3D-MEDNEs). In this previous work, quantitative structure-toxicity relationship (QSTR) techniques allowed us to link 3D-MEDNEs with blood toxicological properties of drugs. In this second part, we extend 3D-MEDNEs to numerically encode biologically relevant information present in MS of the serum proteome for the first time. Using the same idea behind QSTR techniques, we can seek now by analogy a quantitative proteome-toxicity relationship (QPTR). The new QPTR models link MS 3D-MEDNEs with drug-induced toxicological properties from blood proteome information. We first generalized Randic's spiral graph and lattice networks of protein sequences to represent the MS of 62 serum proteome samples with more than 370 100 intensity ( I i ) signals with m/ z bandwidth above 700-12000 each. Next, we calculated the 3D-MEDNEs for each MS using the software MARCH-INSIDE. After that, we developed several QPTR models using different machine learning and MS representation algorithms to classify samples as control or positive Pro-EDICToRs samples. The best QPTR proposed showed accuracy values ranging from 83.8% to 87.1% and leave-one-out (LOO) predictive ability of 77.4-85.5%. This work demonstrated that the idea behind classic drug QSTR models may be extended to construct QPTRs with proteome MS data.

Simple stochastic fingerprints towards mathematical modeling in biology and medicine. 3. ocular irritability classification model

MARCH-INSIDE methodology and a statistical classification method--linear discriminant analysis (LDA)--is proposed as an alternative method to the Draize eye irritation test. This methodology has been successfully applied to a set of 46 neutral organic chemicals, which have been defined as ocular irritant or nonirritant. The model allow to categorize correctly 37 out of 46 compounds, showing an accuracy of 80.46%. Specifically, this model demonstrates the existence of a good categorization average of 91.67 and 76.47% for irritant and nonirritant compounds, respectively. Validation of the model was carried out using two cross-validation tools: Leave-one-out (LOO) and leave-group-out (LGO), showing a global predictability of the model of 71.7 and 70%, respectively. The average of coincidence of the predictions between leave-one-out/leave-group-out studies and train set were 91.3% (42 out of 46 cases)/89.1% (41 out of 46 cases) proving the robustness of the model obtained. Ocular irritancy distribution diagram is carried out in order to determine the intervals of the property where the probability of finding an irritant compound is maximal relating to the choice of find a false nonirritant one. It seems that, until today, the present model may be the first predictive linear discriminant equation able to discriminate between eye irritant and nonirritant chemicals.